# Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF

> **NCT02808585** · PHASE2 · COMPLETED · sponsor: **PhaseBio Pharmaceuticals Inc.** · enrollment: 29 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** PB1046 Injection
- **DRUG:** Placebo Injection

## Key facts

- **NCT ID:** NCT02808585
- **Lead sponsor:** PhaseBio Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2017-12-06
- **Final completion:** 2017-12-06
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2022-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02808585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02808585, "Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02808585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*